'/%3E%3C/svg%3E%0A){kind=small}
Fueled by a deep scientific expertise built over decades of research, Prothena is integrating scientific insights around protein dysregulation to advance a pipeline of therapeutic candidates for a number of neurodegenerative and rare peripheral amyloid diseases which affect millions of people and their families worldwide.
Prothena’s wholly owned programs include a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012 that targets Aβ (amyloid beta) and PRX123, the company’s dual Aβ-tau vaccine. Prothena’s collaborations include prasinezumab, which targets alpha-synuclein, with Roche for the potential treatment of Parkinson’s disease; coramitug (PRX004) for the potential treatment of ATTR amyloidosis with Novo Nordisk; and programs that target tau (BMS-986446/PRX005) and an undisclosed target (PRX019) with Bristol Myers Squibb for the potential treatment of neurodegenerative diseases.
Program/Indication
Protein Target
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
Global Partner3
PrasinezumabParkinson’s disease
α-Synuclein
(C-terminus)
Transthyretin
(misTTR)
PRX019Neurodegeneration
Undisclosed Target
UndisclosedAD in Down syndrome
Undisclosed Target
Aβ, Abeta; AD, Alzheimer’s disease; mAb, monoclonal antibody.
1 Orphan Drug Designation granted by FDA & EMA; 2 FDA Fast Track designation; 3 In July 2021 Novo Nordisk acquired coramitug (formerly PRX004) and broader ATTR amyloidosis program and gained full worldwide rights. Prothena is eligible to receive up to $1.23 billion in total consideration.
mAb
Small Molecule
Vaccine
